Company intelligence / Profile preview
Interprotein Corporation
Osaka, Osaka, Japaninterprotein.com ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Preclinical
01
Overview
Approximately 11% of compounds designed by Interprotein were confirmed to bind to target proteins in assessment with Takeda, which is higher than typical hit rates for computational drug design methods.
- Therapeutic areas
- OncologyImmunologyHematology
- Modalities
- Small moleculespeptides (specifically helix-loop-helix type conformationally-constrained peptides)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Takeda Pharmaceutical Company LimitedSPERA PHARMA, Inc.
Beyond the preview
Go deeper on Interprotein Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Interprotein Corporation.